HARP Study: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 22: | Line 22: | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | [[Category:Clinical trials]] | ||
[[Category:HDLpedia]] | |||
Latest revision as of 14:36, 21 October 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
HARP Study On the Web |
|
American Roentgen Ray Society Images of HARP Study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
The Harvard Atherosclerosis Reversibility Project (HARP) aimed at studying the effect of intensive lipid lowering therapy in normocholesterolemic patients and its effect on angiographic progression of atherosclerosis.
Methods
HARP was a randomized placebo-controlled trial wherein 91 normocholesterolemic patients, with total serum cholesterol levels less than 250 mg/dL, were selected and treated with a stepwise regimen of diet, pravastatin, nicotinic acid, cholestyramine and gemfibrozil for 2.5 years. Repeat coronary angiograms were performed to assess the progression of coronary atherosclerosis.
Results
The study found a significant improvement in total cholesterol, LDL-C and HDL-C levels, however repeat coronary angiograms did not show significant differences in the degree of coronary obstruction, progression of coronary stenosis, regression and clinical cardiac events.
Conclusion
This study concluded that intensive lipid lowering therapy does not alter the rate of progression of coronary stenoses in normocholesterolemic patients.[1][2][3][4]
References
- ↑ Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH (1994). "Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group". Lancet. 344 (8931): 1182–6. PMID 7934538. Unknown parameter
|month=ignored (help) - ↑ Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC (1995). "Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group". J. Am. Coll. Cardiol. 25 (7): 1492–8. PMID 7759696. Unknown parameter
|month=ignored (help) - ↑ Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH (1995). "The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group". Am. J. Cardiol. 76 (9): 78C–85C. PMID 7572692. Unknown parameter
|month=ignored (help) - ↑ Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM (1996). "Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group". Ann. Intern. Med. 125 (7): 529–40. PMID 8815751. Unknown parameter
|month=ignored (help)